The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency

Journal of the American Medical Directors Association

Volumn 5, Issue 6, 2004, Pages 382-386

  Drinka, Paul J ^a  

^a Wisconsin Department of Veterans Affairs   (United States)

Author keywords

Osteoporosis; Parathyroid hormone; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; CREATININE; ERGOCALCIFEROL; ESTROGEN; GESTAGEN; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO; PYRIDINOLINE; VITAMIN D;

AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG SAFETY; FALLING; FRACTURE; GENERAL PRACTITIONER; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; NON PROFIT ORGANIZATION; OSTEOLYSIS; OSTEOPOROSIS; PRACTICE GUIDELINE; SCREENING TEST; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT PLANNING; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

25-HYDROXYVITAMIN D 2; AGED; GLOMERULAR FILTRATION RATE; HOMES FOR THE AGED; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; NURSING HOMES; OSTEOPOROSIS; PARATHYROID HORMONE; RISK FACTORS; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 9444251814     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70006-7     Document Type: Article

References (47)

1. Chandler JM, Zimmerman SI, Girman CJ, et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 2000;284:972-977.
2. Kasiske BL, Chavers B, Rosenberg M, et al., eds. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S12.
3. Vieth R. Problems with direct 25-hydroxyvitamin D assays, and the target amount of vitamin D nutrition desirable for patients with osteoporosis [Letter]. Osteoporos Int 2000;11:635-636.
4. McKenna MJ, Freaney R. Response to Dr. Vieth [Letter]. Osteoporos Int 2000;11:636.
5. Arnold SV, Kiel DP, Chen TC, et al. A randomized placebo-controlled trial of vitamin D supplementation among elderly long-term care residents. J Am Geriatr Soc 2002;50:144.
6. Hamdy NAT, Kanis JA, Beneton NC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358-363.
7. Riggs BL, Melton LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983;75:899-901.
8. Ledger GA, Burritt MF, Kao PC, et al. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 1995;80:3304-3310.
9. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87:4431-4437.
10. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency [Letter]. N Engl J Med 2003;348:1503-1504.
11. Stein MS, Flicker L, Scherer SC, et al. Relationships with serum parathyroid hormone in old institutionalized subjects. Clin Endocrinol 2001; 54:583-592.
12. Stein MS, Scherert SC, Walton L, et al. Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol 1996;44:375-383.
13. Schoofs MWCJ, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003;139:476-482.
14. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281: 1505-1511.
15. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-783.
16. Gallagher JC, Kinyamu HK, Fowler SE, et al. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res 1998;13:475-482.
17. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7:439-443.
18. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 1997;65:67-71.
19. Recker RR, Davies M, Dowd RM, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial. Ann Intern Med 1999;130:897-904.
20. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340.
21. 3 treatment for 3 years on hip fractures in elderly women. BMJ 1994; 308:1081-1082.
22. Musher J, Ousley M, Levenson S, American Health Care Association and American Medical Directors Association. Osteoporosis, Clinical Practice Guideline, 2004. J Am Med Dir Assoc, 2004.
23. Gloth FM, Gundberg CM, Hollis BW, et al. Vitamin D deficiency in homebound elderly persons. JAMA 1995;274:1683-1686.
24. Kinyamu HK, Gallagher JC, Balhorn KE, et al. Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes. Am J Clin Nutr 1997; 65:790-797.
25. Boonen S, Broos P, Verbeke G, et al. Calciotropic hormones and markers of bone remodeling in age-related (type II) femoral neck osteoporosis: Alterations consistent with secondary hyperparathyroidism-induced bone resorption. J Gerontol A Biol Sci Med Sci 1997;52:M286-M293.
26. Waern E, Haug E, Lindstedt G, et al. Increased risk for secondary hyperparathyroidism in hip fracture patients. ASBMR 21st Annual Meeting, St Louis, September 30-Oct 4, 1999. Abstract SU333, p. S515.
27. Akesson K, Vergnaud P, Gineyts E, et al. Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 1993;53: 162-169.
28. Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 2000;132:345-353.
29. McKane WR, Khosla S, Egan KS, et al. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab 1996;81:1699-1703.
30. 3. J Clin Endocrinol Metab 1994; 79:211-216.
31. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 2003;88:185-191.
32. Bischoff-Ferrari HA, Borchers M, Gudat F, et al. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004;19:265-269.
33. Stein MS, Wark JD, Scherer SC, et al. Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. J Am Geriatr Soc 1999;47:1195-1201.
34. Flicker L, Mead K, MacInnis RJ, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003;51:1533-1538.
35. Sambrook PN, Chen JS, March LM, et al. Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab 2004;89:1572-1576.
36. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
37. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc 2003;51:1219-1226.
38. Meunier PJ. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomized clinical trials. Int J Clin Pract 1999;53:122-129.
39. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
40. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676.
41. Havel RJ, Calloway DH, Gussow JD, Subcommittee on the Tenth Edition of the RDAs. Fat Soluble Vitamins. Recommended Dietary Allowances. Washington, DC: National Academy Press; 1989: 78-124.
42. Vieth R, Pak-Chan PCR, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288-294.
43. Trivedi DP, Doll R, Khaw KT. Effect of 4 monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003;326:469-475.
44. Ensrud KE, Balck DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-1624.
45. Shepherd J, Glauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630.
46. Eaton CB, Lapane KL, Murphy JB, et al. Effect of statin (HMG-Co-A-reductase inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes. J Am Geriatr Soc 2002;50:1389-1395.
47. Black DM, Thompson DE, Baue DC. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial: FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124.